Health Care Reform's 340B Provisions Could Impact Oncology Near-Term
Companies with oncology products should take a look at the health reform law's provisions on the 340B drug discount program when assessing the new law's early impact, a review by the consulting firm KantarHealth suggests
You may also be interested in...
The recently signed health care reform law will enable private payers to seek deeper discounts on drugs than they often can now, because the law, in effect, creates a lower "best price" floor for drugs by increasing the base Medicaid drug rebate to 23.1 percent
The health care reform legislation signed into law by President Obama March 23 paves the way for the launch of biosimilar drugs in the U.S., action that could save the country's health care system billions of dollars, while presenting both challenges and opportunities for the drug industry
It has been a long haul to get to the final iteration of proposed health care reform legislation released March 18, and it appears that the pharmaceutical industry's patience and lobbying efforts have garnered an overall positive result